Sonoma pharmaceuticals reports fiscal year and fourth quarter 2024 financial results

Revenues increased 14% in q4 2024 compared to q4 2023 gross profit margin improved 3% in fy 2024 compared to fy 2023 net loss improved 18% in q4 2024 compared to q4 2023, and 6% in fy 2024 compared to fy 2023 boulder, co / accesswire / june 17, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa),a global healthcare leader developing and producing patented microcyn® technology-based stabilized hypochlorous acid (hocl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2024 and the fourth quarter ended march 31, 2024. "we are pleased to report continued product-related growth and reduced cash burn in both our fourth quarter and fiscal year 2024 results.
SNOA Ratings Summary
SNOA Quant Ranking